Gopaldas Visram & Co., Ltd. - 721755 - 06/02/2026

Why It Matters

The violations jeopardize patient safety and could block the company’s products from the U.S. market, underscoring the critical need for rigorous CGMP compliance in global drug supply chains.

Key Takeaways

• FDA cited CGMP quality‑control failures for talc‑containing OTC drugs
• Infrared spectra lacked required wavenumber peaks, raising data integrity concerns
• Non‑conforming talc lots were released, violating USP asbestos specifications
• Firm must submit remediation plan within 15 days or face import bans

Pulse Analysis

The FDA’s recent warning to Gopaldas Visram & Co. highlights a growing regulatory focus on talc‑related contaminants in over‑the‑counter medicines. Asbestos, a known carcinogen, can accompany naturally occurring talc, and the agency’s strict USP monograph requirements demand precise infrared spectroscopy to confirm purity. Recent high‑profile recalls have amplified scrutiny, prompting the FDA to enforce data‑integrity standards that leave little room for procedural shortcuts. Companies that fail to meet these benchmarks risk product detentions, costly recalls, and damage to brand reputation.

For Indian manufacturers, the letter signals a broader shift toward tighter oversight of contract testing arrangements. The FDA expects the originating firm to retain full authority over all quality‑control activities, even when third‑party labs are involved. This means establishing robust qualification programs, conducting independent verification of supplier certificates, and maintaining transparent audit trails. Failure to do so not only violates 21 CFR parts 210 and 211 but also exposes firms to cross‑border trade barriers, as U.S. customs can refuse admission of adulterated articles under section 801(a)(3).

Remediation will require a multi‑phase approach: immediate gap analysis of test methods, retrospective testing of all talc‑containing batches, and a revised CAPA system that enforces thorough OOS investigations. Companies must also consider reformulating products to eliminate high‑risk excipients like talc, thereby reducing future compliance burdens. By addressing these deficiencies promptly, Gopaldas Visram can restore FDA confidence, maintain market access, and set a precedent for stronger quality governance across the Indian pharmaceutical sector.